Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

European Google Rivals Want EU Tech Law Used in Antitrust Case

-Reuters https://www.reuters.com/technology/exclusive-scores-google-rivals-want-eu-tech-law-used-antitrust-case-letter-2022-10-17/

byCharles Gross

October 17, 2022

1 minute read

-Reuters

https://www.reuters.com/technology/exclusive-scores-google-rivals-want-eu-tech-law-used-antitrust-case-letter-2022-10-17/

Stifel Initiates Coverage On ProFrac Holding with Buy Rating, Announces Price Target of $24

By Benzinga Newsdesk

Today, 2:47 AM

Stifel analyst Stephen Gengaro initiates coverage on ProFrac Holding (NASDAQ:PFHC) with a Buy rating and announces Price Target of $24.

PFHC

Coinbase Says It Sees 2022 Revenue Down More Than 50% Vs 2021

By Benzinga Newsdesk

Today, 2:47 AM

- Bloomberg

COIN

CRISPR Therapeutics Q4 EPS $(1.41) Beats $(2.30) Estimate, Sales $6.00K Miss $7.12M Estimate

By Benzinga Newsdesk

Today, 2:47 AM

CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.41) per share which beat the analyst consensus estimate of $(2.30) by 38.7 percent. This is a 23.37 percent increase over losses of $(1.84) per share

CRSP

Beachbody Company Says For Q1 Anticipates Reporting Revenue And Adjusted EBITDA To Be Slightly Ahead Of Its Previous Guidance

By Benzinga Newsdesk

Today, 2:47 AM

Collyns' departure is not related to any disagreement with the company's accounting principles, practices, or financial statement disclosures. The Company will announce its first quarter financial

BODY

European Google Rivals Want EU Tech Law Used in Antitrust Case

Related Posts

Stifel Initiates Coverage On ProFrac Holding with Buy Rating, Announces Price Target of $24

Coinbase Says It Sees 2022 Revenue Down More Than 50% Vs 2021

CRISPR Therapeutics Q4 EPS $(1.41) Beats $(2.30) Estimate, Sales $6.00K Miss $7.12M Estimate

Beachbody Company Says For Q1 Anticipates Reporting Revenue And Adjusted EBITDA To Be Slightly Ahead Of Its Previous Guidance